J&J's suffering Invokana scores new kidney disease nod. Can it turn sales around?

Johnson & Johnson's once-blockbuster SGLT2 diabetes drug Invokana has struggled due to a FDA black-box warning for amputation risks. But now the med has a label expansion its rivals in the class can't match in diabetic kidney disease.